  | Today's Top Story |  |  | |  | The Business Platinum Card® from American Express OPEN
Spending power for your business. Premium benefits for you.
Access a portfolio of 30+ premium benefits, including:
• Complimentary Airport Club Access
• Annual $200 Airline Fee Credit for any airline
• Built-in upgrades at FINE HOTELS & RESORTS
Business Platinum Card
APPLY NOW |
  - HIV vaccine is cleared for human testing
The FDA has approved human testing of SAV001, an HIV vaccine developed by University of Western Ontario researchers in partnership with South Korean biotech firm Sumagen. The Phase I trial, scheduled next month, will evaluate the vaccine's safety in 40 volunteers. The vaccine induced a strong immune response in animals without causing adverse effects. The Globe and Mail (Toronto) (12/21)       - Study links gene mutation to several cancers
Canadian researchers have discovered the occurrence of DICER1 gene mutation in several seemingly unrelated cancers including ovarian, muscle, testicular and uterine cancers. The findings of the study, which appears in the New England Journal of Medicine, suggest that a single treatment targeting the mutant gene could treat "a range of cancers that no one ever thought of treating together," said pathologist and lead researcher David Huntsman. Metro (Canada) (12/21) - Researchers create stem cell model of multiple sclerosis
The world's first multiple sclerosis stem cell model has been developed by Australian scientists using skin cells from MS patients. The development has the potential to provide researchers with an unlimited supply of cells for studying MS and testing new drugs, said Claude Bernard, deputy director of the immunology and stem cell lab at Monash University. The study appears in Stem Cell Research. The Sydney Morning Herald (Australia) (12/22)  | Principles of Checkweighing - Building an Effective Program
This essential guide is an invaluable resource of checkweighing information and a definitive reference providing an insight into all aspects of checkweighing from basic principles to implementation of a comprehensive program. Request your free copy now! |
 - Excelimmune secures $12M from investor
Excelimmune has raised $12 million from a private investor. Proceeds will be used to finance Excelimmune's infectious disease program and discovery of new drug candidates. One of the drugs being developed by Excelimmune is Staphguard, its human recombinant polyclonal antibodies designed to target methicillin-resistant Staphylococcus aureus. American City Business Journals/Boston (12/20)  | Your job as an Exchange administrator isn't easy. You have to respond to lost messages, handle email discovery requirements, and keep everything up and running. Is there an easy way to manage your Exchange environment — and do it under budget? Learn about the challenges faced by three real organizations, and how using the right solution brought them peace of mind. |
 - AstraZeneca signs deals with 2 Asian drugmakers
AstraZeneca will pay $20 million initially for worldwide rights to co-develop and market volitinib, a targeted cancer drug from Hutchison China MediTech. Separately, AstraZeneca obtained an option to acquire Astellas Pharma's diabetes compounds PSN821 and PSN842. Reuters (12/21) - Pall buys analytical systems maker ForteBio
Pall is set to purchase ForteBio, an analytical systems provider for biotech drug discovery and development. The deal will strengthen Pall's capabilities in the markets of biopharmaceutical process monitoring and protein research as it gains access to ForteBio's label-free protein analysis devices. The sale is expected to close by February. Pharmaceutical Business Review Online (12/20)  | Where there's smoke... Achieving safe and reliable operations with enterprise asset management
Chemical and petroleum companies often view risk management through a limited health, safety and environmental lens, but an IBM Institute for Business Value study reveals a distinct correlation between integrated risk management and market performance. Learn more. |
| Food & Agriculture | | | | - USDA to deregulate Monsanto biotech drought-tolerant corn
The Animal and Plant Health Inspection Service of the U.S. Department of Agriculture is expected to announce the deregulation of Monsanto's genetically engineered drought-resistant corn. MON 87460 corn "is unlikely to present a plant pest risk and (APHIS) is therefore determining non-regulated status," the inspection service said. The drought-tolerant trait was developed by Monsanto in partnership with BASF. Agri-Pulse.com (12/21) | Industrial & Environmental | | | | - Report: E10 "blend wall" could make D6 RINs more expensive
The expected saturation of the domestic ethanol market likely will push up the cost of D6 renewable identification numbers, which represent the broader "other" biofuels category, according to a report from Hart Energy. "[O]bligated parties would rather pay a little more for D6 RINs than a lot more for the other RIN types," said Paul Niznik, biofuels manager for Hart Energy. "Without E15 use, refiners will try to blend as much ethanol as possible, but they will eventually have to use more biodiesel or other more expensive fuels to meet the RIN requirements," Niznik said. EthanolProducer.com (12/21) | News from BIO | | | | - Are you taking full advantage of your membership?
BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here.
| SmartQuote | | | |  | Things don't turn up in this world unless somebody turns them up."
--James A. Garfield,
20th U.S. president  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Wednesday, December 21, 2011
- Tuesday, December 20, 2011
- Monday, December 19, 2011
- Friday, December 16, 2011
- Thursday, December 15, 2011
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2011 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment